Association between clinic-level quality of care and patient-level outcomes in multiple sclerosis
暂无分享,去创建一个
[1] V. Tomassini,et al. Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis , 2019, JAMA neurology.
[2] Gavin Giovannoni,et al. International consensus on quality standards for brain health-focused care in multiple sclerosis , 2018, Multiple sclerosis.
[3] Pierre Grammond,et al. Silent lesions on MRI imaging – Shifting goal posts for treatment decisions in multiple sclerosis , 2018, Multiple sclerosis.
[4] R. Osborne,et al. The role of health literacy in explaining the association between educational attainment and the use of out-of-hours primary care services in chronically ill people: a survey study , 2018, BMC Health Services Research.
[5] G. Launoy,et al. Socio-economic status influences access to second-line disease modifying treatment in Relapsing Remitting Multiple Sclerosis patients , 2018, PloS one.
[6] M. Greenwood,et al. Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments , 2017, Front. Neurol..
[7] T. Eikemo,et al. Exploring the differences in general practitioner and health care specialist utilization according to education, occupation, income and social networks across Europe: findings from the European social survey (2014) special module on the social determinants of health , 2017, European journal of public health.
[8] L. Kappos,et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. , 2016, Multiple sclerosis and related disorders.
[9] L. Lönn,et al. Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society , 2016, Acta neurologica Scandinavica.
[10] M. Zaffaroni,et al. Variations in multiple sclerosis practice within Europe - Is it time for a new treatment guideline? , 2016, Multiple sclerosis and related disorders.
[11] Pierre Grammond,et al. Defining reliable disability outcomes in multiple sclerosis. , 2015, Brain : a journal of neurology.
[12] F. Barkhof,et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process , 2015, Nature Reviews Neurology.
[13] J. Hillert,et al. The Swedish MS registry – clinical support tool and scientific resource , 2015, Acta neurologica Scandinavica.
[14] T. Kalincik. Multiple Sclerosis Relapses: Epidemiology, Outcomes and Management. A Systematic Review , 2015, Neuroepidemiology.
[15] D. Centonze,et al. Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group. , 2015, Multiple sclerosis and related disorders.
[16] Xinyue Qin,et al. Systematic Review of Clinical Practice Guidelines Related to Multiple Sclerosis , 2014, PloS one.
[17] Thomas Kohlmann,et al. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis , 2013, BMC Neurology.
[18] A. P. D. Ponce de Leon,et al. Socioeconomic differences in healthcare utilization, with and without adjustment for need: An example from Stockholm, Sweden , 2013, Scandinavian journal of public health.
[19] I. Sperduti,et al. The importance of physician–patient relationship for improvement of adherence to long-term therapy: data of survey in a cohort of multiple sclerosis patients with mild and moderate disability , 2012, Neurological Sciences.
[20] C. Pozzilli,et al. Real‐life impact of early interferonβ therapy in relapsing multiple sclerosis , 2009, Annals of neurology.
[21] L. Kappos,et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS , 2006, Neurology.
[22] J. Wolinsky,et al. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8‐year data , 2005, Acta neurologica Scandinavica.
[23] A Thompson,et al. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. , 2001, Brain : a journal of neurology.